A Large, Community-Based, Open-Label Trial of Donepezil in the Treatment of Alzheimer’s Disease

Publisher： Karger

E-ISSN： 1421-9824|16|1|15-24

ISSN： 1420-8008

Source： Dementia and Geriatric Cognitive Disorders, Vol.16, Iss.1, 2003-05, pp. : 15-24

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-Term Safety and Efficacy of Donepezil in Patients with Severe Alzheimer’s Disease: Results from a 52-Week, Open-Label, Multicenter, Extension Study in Japan

By  

Dementia and Geriatric Cognitive Disorders, Vol. 27, Iss. 3, 2009-02 ,pp. : 232-239

Karger

Access to resources Recommend Favorite

A Double-Blind Placebo-Controlled Randomized Trial of Melissa officinalis Oil and Donepezil for the Treatment of Agitation in Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 31, Iss. 2, 2011-02 ,pp. : 158-164

Karger

Access to resources Recommend Favorite

The Effects of Donepezil in Alzheimer’s Disease – Results from a Multinational Trial1

By  

Dementia and Geriatric Cognitive Disorders, Vol. 10, Iss. 3, 1999-05 ,pp. : 237-244

Karger

Access to resources Recommend Favorite

An Open-Label, Multicenter Observational Study for Patients with Alzheimer’s Disease Treated with Memantine in the Clinical Practice

By  

Dementia and Geriatric Cognitive Disorders Extra, Vol. 1, Iss. 1, 2011-01 ,pp. : 10-19

Karger

Access to resources Recommend Favorite

Economic Evaluation of Donepezil Treatment for Alzheimer’s Disease in Japan

By  

Dementia and Geriatric Cognitive Disorders, Vol. 13, Iss. 1, 2001-12 ,pp. : 33-39

Karger

Access to resources Recommend Favorite